Hematologic, hepatic, and renal function changes in hospitalized patients with Middle East respiratory syndrome coronavirus [PDF]
, 2017 Background There are no longitudinal data on the changes in hematologic, hepatic, and renal function findings in patients with Middle East respiratory syndrome coronavirus (MERS‐CoV) infection. Methods This is a retrospective cohort study of 16 MERS‐
Abbasi, S. +5 more
core +1 more source
Middle East respiratory syndrome coronavirus: current situation and travel-associated concerns [PDF]
, 2016 This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A. +2 more
core +1 more source
Mers-Cov Pcr/Sequencing Primers [PDF]
Protocol Exchange, 2014 Authors: Rachel Graham ### Abstract This protocol details the primers and conditions used for forward and reverse PCR amplification and sequencing of MERS-CoV genomes. ### Introduction This protocol details the steps, reagents, and conditions required to sequence MERS-CoV genomes in the forward and reverse directions.
Rachel Graham, Rachel Graham
openaire +2 more sources
Journal of Family Medicine and Primary Care, 2019 Background: Human coronaviruses (hCoV) usually cause mild to moderate upper respiratory tract illnesses. The novel coronavirus (nCoV), or Middle East respiratory syndrome coronavirus (MERS-CoV), is a particular strain different from any other known hCoV ...
Saad Al-Amri +5 more
doaj +1 more source
Comparing the Immunogenicity and Protective Effects of Three MERS-CoV Inactivation Methods in Mice
Vaccines, 2022 The Middle East respiratory syndrome (MERS) is a fatal acute viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, no vaccine has been approved for MERS-CoV despite continuing outbreaks.
Nayoung Kim +6 more
doaj +1 more source
Prediction of Intrinsic Disorder in MERS-CoV/HCoV-EMC Supports a High Oral-Fecal Transmission [PDF]
, 2013 A novel coronavirus, MERS-CoV (NCoV, HCoV-EMC/2012), originating from the Middle-East, has been discovered. Incoming data reveal that the virus is highly virulent to humans.
Dunker, A. Keith +2 more
core +1 more source
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection
Vaccine, 2017 The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces
Coleman, Christopher M. +6 more
openaire +2 more sources
A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge
Virology Journal, 2022 Abstract Background Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans, with a case fatality rate of approximately 35%, thus posing a considerable threat to public health.
Jung-Eun Park +4 more
openaire +3 more sources
A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]
, 2019 Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y. +2 more
core +1 more source
Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014 [PDF]
, 2014 BACKGROUND: In May 2014, Middle East respiratory syndrome coronavirus (MERS-CoV) infection, with closely related viral genomes, was diagnosed in two Dutch residents, returning from a pilgrimage to Medina and Mecca, Kingdom of Saudi Arabia (KSA).
Arianne B van Gageldonk-Lafeber +14 more
core +7 more sources